10% off for first time customers! Use code “daytrypfirst” at checkout.
The psychedelic therapy landscape is expanding, but ketamine, psilocybin, and MDMA are at very different stages.
This article explains how they work, what research shows, where they stand legally, and what patients can realistically access today.
Psychedelic-assisted therapy combines a psychoactive substance with professional support to address mental health concerns. The experience is structured around medical screening, preparation, supervision, and follow-up rather than simply taking a substance.
Ketamine primarily affects NMDA and glutamate signaling. Psilocybin acts mainly on serotonin receptors, while MDMA affects serotonin and other systems involved in mood and emotional processing.
Ketamine currently has the clearest path to patient access because it is an FDA-approved anesthetic that can also be prescribed off-label. However, ketamine itself is not FDA-approved for psychiatric conditions. Esketamine, a related medication, is FDA-approved for certain forms of depression.
Qualified patients may also access ketamine therapy from home through telehealth programs. Depending on the provider, treatment can involve prescribed ketamine troches or nasal formulations, medical evaluation, treatment instructions, and follow-up support.
Psilocybin is the psychedelic compound found in certain mushrooms. Research shows that when combined with psychological support, it reduces depressive symptoms in adults with major depressive disorder.
However, psilocybin remains a federally controlled Schedule I substance and is not currently an FDA-approved treatment.
MDMA-assisted therapy has also shown promising results, particularly for PTSD. Studies show greater improvements in PTSD symptoms in patients with MDMA-assisted therapy than with therapy using placebo.
Despite this research, MDMA remains Schedule I federally and is not currently an FDA-approved treatment. Routine patient access therefore remains limited.
For people asking which option is actually available now, ketamine generally has the most established route to treatment. Qualified patients can be evaluated through licensed providers offering in-person or online ketamine treatment, including certain telehealth programs.
Psilocybin and MDMA remain primarily research-based options, with access generally limited to clinical trials or legally authorized programs.
The psychedelic therapy landscape is developing quickly, but access still depends heavily on the substance, research stage, and current regulations. For patients interested in exploring an established option today, ketamine offers a more practical path than psilocybin or MDMA, with treatment available through qualified medical providers.
Daytryp RX provides a convenient telehealth approach to ketamine therapy from home, beginning with an online medical consultation and provider evaluation to determine whether treatment is appropriate.
Take the first step toward exploring your treatment options; contact us today.
